#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Epileptic encephalopathy Sexually transmitted disease Ewing's sarcoma recurrent Duchenne muscular dystrophy gene carrier Nodal marginal zone B-cell lymphoma B-cell small lymphocytic lymphoma recurrent Partial lipodystrophy Medulloblastoma Biotinidase deficiency Hyperoxaluria Allogenic stem cell transplantation Peripheral primitive neuroectodermal tumour of soft tissue Neuroendocrine carcinoma C3 glomerulopathy Familial hypertriglyceridaemia More trials…

    Learn about Rare Diseases

    Idiopathic inflammatory myopathy – Treatment Osteosarcoma recurrent – Treatment Haemophilia B without inhibitors – Life with Disease Biotinidase deficiency – Treatment Sarcoma – Trials in Disease Ewing’s sarcoma – Basic Information Ehlers-Danlos syndrome – Life with Disease Advanced systemic mastocytosis – Treatment Medulloblastoma recurrent – Life with Disease Leiomyosarcoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Afatinib Asparaginase Bi-1910 Bi 706321 Ephedrine Hydrochloride Sunitinib Cefuroxime Axetil GAXILOSE Glycerol Phenylbutyrate Folinic Acid Nms-03592088 Xxb750 Cx-037231 Sodium Valproate Bempedoic Acid POLYSORBATE 80 Entecavir Milvexian Bromhexine Hydrochloride His203-Crm197 More therapies…

    Learn about Your Condition

    Proteinuria Huntington's disease Oxygen saturation Prodromal Alzheimer's disease Mast cell activation syndrome Arthroscopy Carpal tunnel syndrome Malignant melanoma stage II Mitral valve prolapse Glomerulonephritis membranous Lumbosacral radiculopathy Eosinophilic oesophagitis Osteoarthritis Underweight Meniere's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Reumedika s.c.

Reumedika s.c.

Ul. Wejherowska 16, Poznan, 60-446, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

    Recruiting

    3 1
    Investigated Drugs:
    • Zasocitinib
    Belgium Bulgaria Croatia Czechia Estonia France +7

  • Efficacy of intra‑articular allogeneic peripheral blood mononuclear cells induced to an early apoptotic state versus placebo in adults with primary knee osteoarthritis

    Recruiting

    2 1
    Investigated Drugs:
    • Allogeneic Peripheral Blood Mononuclear Cells Induced To An Early Apoptotic State
    Denmark Poland

  • Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines

    Recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Zasocitinib
    • Apremilast
    Belgium Bulgaria Croatia Czechia Estonia Germany +6

  • Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

    Recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Risankizumab
    • Sonelokimab
    Bulgaria Czechia France Germany Hungary Poland +1

  • A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Sonelokimab
    Bulgaria Croatia Czechia Estonia Finland France +10

  • Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Etanercept
    Bulgaria Hungary Poland Romania

  • Study on the Effects of LNA043 for Patients with Knee Osteoarthritis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Osteoarthritis
    Investigated Drugs:
    • Lna043
    Czechia Denmark Estonia Poland Spain

  • Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Sonelokimab
    Bulgaria Croatia Czechia Estonia Finland France +10

  • Study on the Effects of Abiprubart for Patients with Sjögren’s Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Kpl-404
    Czechia France Germany Hungary Poland Spain

  • Study on the Effects of AP1189 and Methotrexate for Patients with Early Rheumatoid Arthritis and Active Inflammation

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Resomelagon
    • Methotrexate
    Bulgaria Czechia Denmark Poland Romania
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!